The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | On-body injector delivery of subcutaneous isatuximab in multiple myeloma
Enrique Ocio, MD, PhD, Marqués de Valdecilla University Hospital, Santander, Spain, discusses the use of an on-body injector (OBI) for subcutaneous isatuximab in patients with multiple myeloma. He highlights its non-inferior efficacy, convenience, and potential to improve treatment adherence and quality of life, while enabling home administration and reducing the burden on patients and healthcare centers. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
The OBI, the body delivery injector for isatuximab, I think it’s a great opportunity we have now. We have tested that in IRAKLIA in some of our studies. So we have a lot of experience now with the OBI in patients treated with this anti-CD38 menopausal antibody. I think this is a great advantage because it’s clean, it’s safe, it’s easy to use. And particularly, well, the data has said that it has the same efficacy...
The OBI, the body delivery injector for isatuximab, I think it’s a great opportunity we have now. We have tested that in IRAKLIA in some of our studies. So we have a lot of experience now with the OBI in patients treated with this anti-CD38 menopausal antibody. I think this is a great advantage because it’s clean, it’s safe, it’s easy to use. And particularly, well, the data has said that it has the same efficacy. I would say there was a non-inferiority trial and it says that it was non-inferior. A good adherence to treatment and quality of life was much better. So the patient decided to continue or wanted to continue with this device. This makes something that I think we are not speaking about something very, very effective or a new effective combination, a new effective drug, a different concept. But this is a different concept for administration. And I think this is also very good because we can have very easily home delivery of the drugs, at the hospital this is easier, but then we have that can do it at home and also I think this facilitates a lot that the patient can administer the self-administration by him, by the patient or her or the caregiver of the drug, I think this also makes a great impact based on what we have been also speaking to in this meeting. This is the safety, tolerability, convenience, quality of life of patients. This would help also a lot.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
